Tracer library / [90Y]Y-FAPI-46
[90Y]Y-FAPI-46
Also written as [90Y]Y-FAPI-46; [Y-90]Y-FAPI-46
- Radionuclide
- Y-90 t½ 3843 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- FAP inhibitor (FAPI) radiotracer
- Target / mechanism
- Fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts PMID 41599688
- Clinical application
- Radioligand therapy targeting FAP-expressing tumours (e.g. solitary fibrous tumours) using 90Y-FAPI-46 PMID 42495195
- Theranostic pair
- [68Ga]Ga-FAPI-46
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| EasyOne Trasis | — | — | 56 ± 5% | >99% | FAPI-46 | 35533534 2022 Nucl Med Biol the cassette based synthesis module Trasis EASYONE - a radiochemical yield of 88 ± 7% and 56 ± 5% |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.2026 · J Nucl Med · Retrospective
- Is FAP the key to unlocking treatment for rare soft-tissue sarcomas?2026 · Am J Nucl Med Mol Imaging · Clinical study
- 90Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors.2025 · J Nucl Med · Case report, multicentre
Need this precursor?We can point you to suppliers for [90Y]Y-FAPI-46, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [90Y]Y-FAPI-46.
Get in touchNotes
Added from reverse module search (stage 6); 4 article(s) with Y-90. Stage set/updated at stage 23 from PMID 41599688: 'Therapeutic evidence shows encouraging tumour retention and safety profiles for agents such as [177Lu]Lu-FAP-2286 and [90Y]Y-FAPI-46, while α-emitting radiotracers (e.g., [225Ac]Ac-FAPI-04) demonstrate potent antitumor effects in preclinical models.'. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'early-stage clinical evidence / investigational'; normalised to 'Clinical research', original wording kept here.